Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 6.11
SRPT's Cash to Debt is ranked lower than
61% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. SRPT: 6.11 )
Ranked among companies with meaningful Cash to Debt only.
SRPT' s 10-Year Cash to Debt Range
Min: 4.43  Med: 10000.00 Max: No Debt
Current: 6.11
F-Score: 2
Z-Score: 7.28
M-Score: -3.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -4970.46
SRPT's Operating margin (%) is ranked lower than
88% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. SRPT: -4970.46 )
Ranked among companies with meaningful Operating margin (%) only.
SRPT' s 10-Year Operating margin (%) Range
Min: -28680.87  Med: -1371.21 Max: -71.16
Current: -4970.46
-28680.87
-71.16
Net-margin (%) -4825.62
SRPT's Net-margin (%) is ranked lower than
88% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. SRPT: -4825.62 )
Ranked among companies with meaningful Net-margin (%) only.
SRPT' s 10-Year Net-margin (%) Range
Min: -27020  Med: -1391.71 Max: -4.93
Current: -4825.62
-27020
-4.93
ROE (%) -73.78
SRPT's ROE (%) is ranked lower than
73% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. SRPT: -73.78 )
Ranked among companies with meaningful ROE (%) only.
SRPT' s 10-Year ROE (%) Range
Min: -309.2  Med: -75.29 Max: -16.44
Current: -73.78
-309.2
-16.44
ROA (%) -62.09
SRPT's ROA (%) is ranked lower than
74% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. SRPT: -62.09 )
Ranked among companies with meaningful ROA (%) only.
SRPT' s 10-Year ROA (%) Range
Min: -184.14  Med: -62.30 Max: -4.62
Current: -62.09
-184.14
-4.62
ROC (Joel Greenblatt) (%) -486.16
SRPT's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. SRPT: -486.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SRPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2075  Med: -556.33 Max: -277.71
Current: -486.16
-2075
-277.71
Revenue Growth (3Y)(%) -52.10
SRPT's Revenue Growth (3Y)(%) is ranked lower than
82% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SRPT: -52.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SRPT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -63.2  Med: 10.50 Max: 383.5
Current: -52.1
-63.2
383.5
EBITDA Growth (3Y)(%) 26.60
SRPT's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. SRPT: 26.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SRPT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -36.3  Med: 1.65 Max: 43.4
Current: 26.6
-36.3
43.4
EPS Growth (3Y)(%) 213.50
SRPT's EPS Growth (3Y)(%) is ranked higher than
100% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. SRPT: 213.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SRPT' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.4  Med: -1.40 Max: 213.5
Current: 213.5
-62.4
213.5
» SRPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SRPT Guru Trades in Q3 2014

Columbia Wanger 3,237,000 sh (+22.94%)
Steven Cohen 691,200 sh (unchged)
Steven Cohen 227,300 sh (-16.46%)
George Soros 325,000 sh (-52.21%)
» More
Q4 2014

SRPT Guru Trades in Q4 2014

Jim Simons 164,278 sh (New)
Steven Cohen 1,551,300 sh (+582.49%)
Steven Cohen 1,826,500 sh (+17.74%)
Columbia Wanger 3,272,400 sh (+1.09%)
Steven Cohen 275,200 sh (unchged)
Columbia Wanger 3,272,400 sh (unchged)
George Soros Sold Out
» More
Q1 2015

SRPT Guru Trades in Q1 2015

Jim Simons 396,539 sh (+141.38%)
Steven Cohen 1,702,200 sh (+9.73%)
Steven Cohen 174,900 sh (unchged)
Columbia Wanger 3,272,400 sh (unchged)
» More
Q2 2015

SRPT Guru Trades in Q2 2015

Columbia Wanger 3,532,677 sh (+7.95%)
Steven Cohen 2,193,600 sh (+28.87%)
Steven Cohen 174,900 sh (unchged)
Jim Simons 295,178 sh (-25.56%)
Steven Cohen 936,600 sh (-44.98%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.44
SRPT's P/B is ranked lower than
76% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. SRPT: 8.44 )
Ranked among companies with meaningful P/B only.
SRPT' s 10-Year P/B Range
Min: 2  Med: 4.62 Max: 234
Current: 8.44
2
234
P/S 1274.31
SRPT's P/S is ranked lower than
99% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. SRPT: 1274.31 )
Ranked among companies with meaningful P/S only.
SRPT' s 10-Year P/S Range
Min: 1.56  Med: 25.46 Max: 2244
Current: 1274.31
1.56
2244
Current Ratio 4.68
SRPT's Current Ratio is ranked higher than
54% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. SRPT: 4.68 )
Ranked among companies with meaningful Current Ratio only.
SRPT' s 10-Year Current Ratio Range
Min: 0.76  Med: 7.59 Max: 36.25
Current: 4.68
0.76
36.25
Quick Ratio 4.68
SRPT's Quick Ratio is ranked higher than
55% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. SRPT: 4.68 )
Ranked among companies with meaningful Quick Ratio only.
SRPT' s 10-Year Quick Ratio Range
Min: 0.76  Med: 7.59 Max: 36.25
Current: 4.68
0.76
36.25
Days Sales Outstanding 240.35
SRPT's Days Sales Outstanding is ranked lower than
91% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. SRPT: 240.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRPT' s 10-Year Days Sales Outstanding Range
Min: 28.22  Med: 90.50 Max: 886.65
Current: 240.35
28.22
886.65

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.38
SRPT's Price/Net Cash is ranked lower than
76% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. SRPT: 15.38 )
Ranked among companies with meaningful Price/Net Cash only.
SRPT' s 10-Year Price/Net Cash Range
Min: 3.03  Med: 6.39 Max: 72.6
Current: 15.38
3.03
72.6
Price/Net Current Asset Value 11.98
SRPT's Price/Net Current Asset Value is ranked lower than
72% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. SRPT: 11.98 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SRPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.95  Med: 6.20 Max: 42
Current: 11.98
2.95
42
Price/Tangible Book 8.73
SRPT's Price/Tangible Book is ranked lower than
70% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. SRPT: 8.73 )
Ranked among companies with meaningful Price/Tangible Book only.
SRPT' s 10-Year Price/Tangible Book Range
Min: 2.41  Med: 4.85 Max: 474
Current: 8.73
2.41
474
Price/Median PS Value 44.12
SRPT's Price/Median PS Value is ranked lower than
99% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. SRPT: 44.12 )
Ranked among companies with meaningful Price/Median PS Value only.
SRPT' s 10-Year Price/Median PS Value Range
Min: 0.08  Med: 2.91 Max: 76.32
Current: 44.12
0.08
76.32
Earnings Yield (Greenblatt) (%) -14.47
SRPT's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. SRPT: -14.47 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SRPT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -53.7  Med: 0.00 Max: 82
Current: -14.47
-53.7
82

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 2 58 150 250
EPS($) -4.48 -3.41 -1.92 -0.95
EPS without NRI($) -4.48 -3.41 -1.92 -0.95

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:AB3A.Germany,
Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.
» More Articles for SRPT

Headlines

Articles On GuruFocus.com
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Feb 16 2013 

More From Other Websites
SAREPTA THERAPEUTICS, INC. Financials Sep 03 2015
Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor Sep 03 2015
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 31 2015
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 31 2015
Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews Aug 27 2015
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review Aug 26 2015
Sarepta Upgraded On Promising Muscular-Dystrophy Drug Aug 26 2015
Sarepta gains after-hours as FDA accepts application for Duchenne drug approval Aug 25 2015
FDA Grants Priority Review to Sarepta Drug Aug 25 2015
Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne... Aug 25 2015
Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne... Aug 25 2015
Piper Jaffray Goes Overweight Sarepta, Expects FDA To Accept Next Key Drug Filing Aug 24 2015
Sarepta Therapeutics upgraded by Piper Jaffray Aug 24 2015
Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA for Eteplirsen for the... Aug 21 2015
Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA for Eteplirsen for the... Aug 21 2015
The FDA Is Basically Approving Everything. Here's The Data To Prove It Aug 20 2015
Treating Female Sexual Dysfunction (And How To Invest In It) Aug 19 2015
Sarepta Therapeutics Made Investors Millionaires in 2 Years Aug 14 2015
Checkmate Pharma is latest cancer drug firm focused on immune system (BBJ photo gallery) Aug 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK